Document:

Exhibit
10.16

 

THIS
CONVERTIBLE PROMISSORY NOTE AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE
OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO
OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF
A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.

 

CONVERTIBLE
PROMISSORY NOTE

 

	$750,000	September
    16, 2022

 

For
value received ONE WORLD PRODUCTS, INC., a Nevada corporation (the “Company”)
promises to pay to the order of Dr. John McCabe (“Holder”) the principal sum of SEVEN HUNDRED FIFTY THOUSAND
DOLLARS (750,000.00), with interest on the outstanding principal amount at the rate of eight percent (8%) per annum, on September 16,
2024 (the Maturity Date”). Interest shall commence with the date hereof and shall accrue on the outstanding principal
amount until paid in full or this Note has been converted as provided below. Interest shall be computed on the basis of a year of 365
days for the actual number of days elapsed.

 

1. All
payments of interest and principal shall be in lawful money of the United States of America. All payments shall be applied first to
accrued interest, and thereafter to principal.

 

2. (a)
The outstanding principal balance of this Note, together with any accrued and unpaid interest thereon, or any portion thereof, may,
at the option of the Holder, be converted into shares of the Series B Preferred Stock of the Company (“Series B
Stock”) at any time at a price per share of Series B Stock of $15.00, as equitably adjusted for any stock split or stock
dividends effected after the date hereof (the “Conversion Price”).

 

(b)
In case of any reorganization, consolidation or merger involving the Company prior to the Maturity Date, in which the stockholders
of the Company receive securities of another entity (including any parent company of the company with which the Company merges or is
merged into) (the “Successor Issuer”) in exchange for their shares of Series B Stock, the Successor Issuer shall
assume the obligations of the Company under this Note, and this Note shall thereafter be convertible into such securities of the
Successor Issuer as the Holder would have been entitled to receive upon consummation of such reorganization, consolidation or
merger, if the Holder had converted all of the principal and interest outstanding under this Note immediately prior thereto at the
Conversion Price.

 

(c)
Before the Holder shall be entitled to convert this Note pursuant to this Section 2, the Holder shall give written notice to
the Company in the form of Annex A hereto at the Company’s principal corporate office, by email, facsimile or otherwise of the
election to convert the same and shall state therein the name or names in which the shares of Series B Stock are to be issued. The
Company shall, as soon as practicable thereafter, issue and deliver to Holder or to the nominee or nominees of Holder, a certificate
or certificates for the Series B Stock to which the Holder shall be entitled as aforesaid. Conversion shall be deemed to have been
effected on the date when delivery of notice of an election to convert. All Series B Stock which may be issued upon conversion of
the Note will, upon issuance, be duly issued, fully paid and non-assessable and free from all taxes, liens, and charges with respect
to the issuance thereof.

 

    	 

    	 

    

 

3. This
Note may be prepaid at any time without the consent of the Holder.

 

4. The
Company shall pay all reasonable attorneys’ fees and court costs incurred by the Holder in enforcing and collecting this
Note.

 

5. The
Company hereby waives demand, notice, presentment, protest and notice of dishonor.

 

6. This
Note shall be governed by and construed under the laws of the State of Nevada, as applied to agreements among Nevada residents, made
and to be performed entirely within the State of Nevada, without giving effect to conflicts of laws principles.

 

7. This
Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed, or accompanied by a duly
executed written instrument of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and
registered in the name of, the transferee, or a new Note for like principal amount and interest shall be issued to, and registered
in the name of, the transferee. Interest and principal shall be paid solely to the registered holder of this Note. Such payment
shall constitute full discharge of the Company’s obligation to pay such interest and principal.

 

	 	ONE
    WORLD PRODUCTS, INC. 
	 	 	 
	 	 	 
	 	By:	/s/
    Isiah L. Thomas, III
	 	Name:
    	Isiah
    L. Thomas, III
	 	Title:
    	Chief
    Executive Officer
	 	 	 
	 	 	 
	 	INVESTOR
	 	 	 
	 	By:	/s/
    Dr. John McCabe
	 	Name:
    	Dr.
    John McCabe

 

    	2

    	 

    

 

ANNEX
A

 

CONVERSION
NOTICE

 

The
undersigned hereby elects to convert principal and/or interest under the Convertible Promissory Note, issued as of September 16, 2022
(the “Note”) of One World Products, Inc., a Nevada corporation (the “Company”), into shares of
Series B Preferred Stock (the “Series B Stock”), of the Company according to the conditions hereof and the Note, as
of the date written below. If shares of Series B Stock are to be issued in the name of a person other than the undersigned, the undersigned
will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested
by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.

 

Conversion
calculations:

 

Date
to Effect Conversion: ________________________________________

 

Principal
Amount of Note to be Converted: __________________________

 

Amount
of Interest of Note to be Converted: __________________________

 

Number of shares of Series B Stock to be issued:

 _____________________________________________________________

 

Signature: _____________________________________________________

 

Name:
________________________________________________________

 

Address
for Delivery of Stock Certificates: 

 _____________________________________________________________

 

    	3Exhibit
4.1

 

AMENDMENT

TO
THE

SECOND
AMENDED AND RESTATED RIGHTS AGREEMENT

OF

AIM
IMMUNOTECH INC.

 

This
Amendment to the Second Amended and Restated Rights Agreement (this “Amendment”) is made this 9th day of November,
2022, by and between AIM ImmunoTech Inc., f/k/a Hemispherx Biopharma, Inc., a Delaware corporation (the “Company’), and American
Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Rights Agent”).

 

WHEREAS,
on November 19, 2002, the Company entered into the original Rights Agreement (the “Original Agreement”) with Continental
Stock Transfer & Trust Company (“CST”) as the rights agent;

 

WHEREAS,
the Company and CST amended and restated the Original Agreement on November 2, 2012 (the “2012 Agreement”);

 

WHEREAS,
on April 26, 2017, the Company terminated CST as the rights agent under the Amended Agreement and appointed AST as the Rights Agent and
AST accepted the appointment;

 

WHEREAS,
the Company and the Rights Agent further amended and restated the 2012 Agreement on November 14, 2017 (as so amended and restated, the
“Rights Agreement”);

 

WHEREAS,
the Board of Directors of the Company (the “Board”) has determined that it is advisable and in the best interests of the
Company and its stockholders to amend the Rights Agreement in accordance with Section 27 thereof; and

 

WHEREAS,
pursuant to its authority under Section 27 of the Rights Agreement, the Board has approved, and directed that the Rights Agent approve,
this Amendment.

 

NOW,
THEREFORE, in consideration of the premises and mutual covenants contained in this Amendment, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Rights Agent hereby agree as follows:

 

1. Definitions.
Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Rights Agreement.

 

    	 

     

    

 

2. Amendment.
Section 7(a) of the Rights Agreement is hereby amended and restated in its entirety to read as follows:

 

(a)
Subject to Section 7(e) hereof, at any time after the Distribution Date the registered holder of any Rights Certificate may exercise
the Rights evidenced thereby (except as otherwise provided herein, including, without limitation, the restrictions on exercisability
set forth in Section 9(c), Section 11(a)(iii) and Section 23(a) hereof) in whole or in part upon surrender of the Rights Certificate,
with the form of election to purchase and the certificate on the reverse side thereof duly executed, to the Rights Agent at the principal
office or offices of the Rights Agent designated for such purpose, together with payment of the aggregate Purchase Price with respect
to the total number of one one-hundredths of a share (or other securities, cash or other assets, as the case may be) as to which such
surrendered Rights are then exercisable, at or prior to the earlier of (i) 5:00 P.M., New York City time, on February 14, 2023 (or such
later date as may be established by the Board of Directors prior to the expiration of the Rights) (such date the “Final Expiration
Date”), or (ii) the time at which the Rights are redeemed or exchanged as provided in Section 23 and Section 24 hereof (the earlier
of (i) and (ii) being herein referred to as the “Expiration Date”).

 

3. Other
Terms. Except as set forth in this Amendment, (i) all provisions of the Rights Agreement shall remain unmodified and in full
force and effect and (ii) nothing contained in this Amendment shall amend, modify or otherwise affect the Rights Agreement or any
party’s rights or obligations contained therein.

 

4. Counterparts.
This Amendment may be executed in any one or more counterparts, each of which shall be deemed an original and all of which shall
together constitute the same instrument.

 

[Signature
page follows.]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed and delivered this Amendment as of the date first above written.

 

	 	AIM IMMUNOTECH INC.
	 	 
	 	By:	/s/ Thomas K. Equels
	 	Name:	Thomas K. Equels
	 	Title:	 Chief Executive Officer
	 	 
	 	American Stock Transfer & Trust Company, LLC
	 	 
	 	By:	/s/ Joseph Dooley
	 	Name:	Joseph Dooley
	 	Title:	 Senior Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]